en · de · es · pt
liraglutide-notes.peptides6088.com › News › Identity And Regulatory Status — Quick Reference

Identity And Regulatory Status — Quick Reference

By Editorial Desk · published 2026-04-07 · last reviewed 2026-05-10 · News

PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Regulatory Status

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516; GW-1516; endurobolGW501516 is the research code
Drug classPPARδ agonistNot a selective androgen receptor modulator
Molecular formulaC21H18F3NO3S2Established chemical formula
Molar mass453.5 g/molCalculated from the formula
Regulatory statusProhibited in sport; not approved as medicineStatus varies by country

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Related pages on this site

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Detection, Regulation, and Quality Context

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Further detail

Many complexes are known with cyclopropenium ligands. Examples include [M(C3Ph3)(PPh3)2]+ (M = Ni, Pd, Pt) and Co(C3Ph3)(CO)3. Such compounds are prepared by reaction of cyclopropenium salts with low valent metal complexes.

Applebaum's introduction has been criticized by Gulag researcher Wilson Bell, stating that her book "is, aside from the introduction, a well-done overview of the Gulag, but it did not offer an interpretative framework much beyond Solzhenitsyn's paradigms".

Glycerol is used in medical, pharmaceutical and personal care preparations, often as a means of improving smoothness, providing lubrication, and as a humectant. Ichthyosis and xerosis have been relieved by the topical use of glycerin. It is found in allergen immunotherapies, cough syrups, elixirs, expectorants, toothpastes, mouthwashes, skin care products, shaving cream, hair care products, soaps, and water-based personal lubricants. It is used to keep tablets and other solid dosage forms from falling apart. For human consumption, glycerol is classified by the FDA among the sugar alcohols as a caloric macronutrient. Glycerol is also used in blood banking to preserve red blood cells prior to freezing. Taken rectally, glycerol functions as a laxative by irritating the anal mucosa and inducing a hyperosmotic effect, expanding the colon by drawing water into it to induce peristalsis resulting in evacuation. It may be administered undiluted as a suppository, or as a small-volume (2–10 ml) enema. Alternatively, it may be administered in a dilute solution, such as 5%, as a high-volume enema. Taken orally (often mixed with fruit juice to reduce its sweet taste), glycerol can cause a rapid, temporary decrease in the internal pressure of the eye. This can be useful for the initial emergency treatment of severely elevated eye pressure. In 2017, researchers showed that the probiotic Limosilactobacillus reuteri bacteria can be supplemented with glycerol to enhance its production of antimicrobial substances in the human gut.

== Measurement == Molar masses are almost never measured directly. They may be calculated from standard atomic masses, and are often listed in chemical catalogues and on safety data sheets (SDS). Molar masses typically vary between:

dolichyl diphosphate + a glycoprotein with the oligosaccharide chain attached by N-glycosyl linkage to protein L-asparagine Thus, the two substrates of this enzyme are dolichyl diphosphooligosaccharide and protein L-asparagine, whereas its 3 products are dolichyl diphosphate, glycoprotein with the oligosaccharide chain attached by N-glycosyl, and linkage to protein L-asparagine. This enzyme belongs to the family of glycosyltransferases, specifically the hexosyltransferases. The systematic name of this enzyme class is dolichyl-diphosphooligosaccharide:protein-L-asparagine oligopolysaccharidotransferase. Other names in common use include dolichyldiphosphooligosaccharide-protein glycosyltransferase, asparagine N-glycosyltransferase, dolichyldiphosphooligosaccharide-protein oligosaccharyltransferase, dolichylpyrophosphodiacetylchitobiose-protein glycosyltransferase, oligomannosyltransferase, oligosaccharide transferase, dolichyldiphosphoryloligosaccharide-protein, and oligosaccharyltransferase. This enzyme participates in n-glycan biosynthesis and glycan structures - biosynthesis 1.

Sources: en.wikipedia.org

Background from the literature

=== Working with governors === As treasurer, Kennedy often clashed with governors and state legislators from both political parties, especially over spending and tax increases. He advocated for reducing state bureaucracy by cutting unnecessary state government jobs. In 2006, Kennedy criticized Governor Kathleen Blanco for including more than $9 million in spending he deemed "pork". He sent Blanco a six-page document of suggested cuts she could make as line-item vetoes. Kennedy said his list was "based upon the fact that many of the entities do not appear to be government entities, the lack of information about many of the items or entities, and that many of the items should have been considered through the entire process and/or included in other appropriate places in the budget to ensure proper public scrutiny, input and accountability." During his third term as treasurer, Kennedy devised a 24-point plan by which the state could save money. Governor Bobby Jindal said Kennedy could "streamline" his own department. Many of Kennedy's ideas were derived from the Louisiana Commission for Streamlining Government, on which he served in his official capacity as treasurer. Kennedy later accused Jindal's administration of check kiting, a controversial accounting practice whereby the governor took money from the 2014-2015 budget to cover debts from the 2013-2014 budget.

=== Monitoring === Keeping MSUD under control requires careful monitoring of blood chemistry, both at home and in a hospital setting. DNPH or specialized dipsticks may be used to test the patient's urine for ketones (a sign of metabolic decompensation), when metabolic stress is likely or suspected. Fingerstick tests are performed regularly and sent to a laboratory to determine blood levels of leucine, isoleucine, and valine. Regular metabolic consultations, including blood draws for full nutritional analysis, are recommended; especially during puberty and periods of rapid growth. MSUD management also involves a specially tailored metabolic formula, a modified diet, and lifestyle precautions such as avoiding fatigue and infections, as well as consuming regular, sufficient calories in proportion to physical stress and exertion. Without sufficient calories, catabolism of muscle protein will result in a metabolic crisis. Those with MSUD must be hospitalized for intravenous infusion of sugars and nasogastric drip-feeding of formula, in the event of metabolic decompensation, or lack of appetite, diarrhea or vomiting. Food avoidance, rejection of formula, and picky eating are all common problems with MSUD. Some patients may need to receive all or part of their daily nutrition through a feeding tube. Appropriate Branched-Chain Amino Acid (BCAA) blood concentrations: LEU plasma concentrations for infants and children 5 years old and younger should be between 75-200 mmol/L.

==== Deep vein thrombosis ==== DVT usually occurs in the veins of the legs, although it can also occur in the deep veins of the arms. Immobility, active cancer, obesity, traumatic damage and congenital disorders that make clots more likely are all risk factors for deep vein thrombosis. It can cause the affected limb to swell, and cause pain and an overlying skin rash. In the worst case, a deep vein thrombosis can extend, or a part of a clot can break off as an embolus and lodge in a pulmonary artery in the lungs, known as a pulmonary embolism. The decision to treat deep vein thrombosis depends on its size, symptoms, and their risk factors. It generally involves anticoagulation to prevents clots or to reduce the size of the clot. Intermittent pneumatic compression is a method used to improve venous circulation in cases of edema or in those at risk from a deep vein thrombosis.

==== Meals ==== Some bodybuilders often split their food intake into 5 to 7 meals of equal nutritional content and eat at regular intervals (e.g., every 2 to 3 hours). This approach serves two purposes: to limit overindulging in the cutting phase, and to allow for the consumption of large volumes of food during the bulking phase. Eating more frequently does not increase basal metabolic rate when compared to 3 meals a day. While food does have a metabolic cost to digest, absorb, and store, called the thermic effect of food, it depends on the quantity and type of food, not how the food is spread across the meals of the day. Well-controlled studies using whole-body calorimetry and doubly labeled water have demonstrated that there is no metabolic advantage to eating more frequently.

In 2003, following the Soccer Australia team's failure to qualify for the 2002 FIFA World Cup, allegations of fraud and mismanagement were levelled at Soccer Australia by elements within the Australian press including the ABC. Soccer Australia commissioned an independent inquiry known as the Crawford Report as a result of the Australian government's threat to withdraw funding to the sport. Any political interference would have constituted a breach of FIFA statutes. The findings of the report were critically analysed by the board of Soccer Australia who believed that the recommendations contained therein were not capable of being implemented. The report recommended, among other things, the reconstitution of the organisation with an interim board headed by prominent businessman Frank Lowy. Some three months after Lowy's appointment, Soccer Australia was placed into liquidation and the Australian Soccer Association (ASA) was created and seized control of the premier soccer competitions and teams without encompassing the Crawford Report recommendations and effectively disenfranchised all other organisations and parties with an interest in Soccer Australia. The Australian government provided approximately $15 million to the ASA. On 1 January 2005, ASA renamed itself Football Federation Australia (FFA), aligning with the international usage of the name "football" in preference to "soccer" and, by a more distinct name, distancing itself from the failings of the former Soccer Australia. It coined the phrase "old soccer, new football" to emphasise this.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Is cardarine approved for human use?

No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.

Why was its development discontinued?

Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.

How does cardarine work in the body?

It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.

Network